Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Theratechnologies Inc > Some thoughts on the financing
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(182)
•••
Comment by Trogarzonon Jul 16, 2022 3:41pm
135 Views
Post# 34829249

RE:RE:RE:Some thoughts on the financing

RE:RE:RE:Some thoughts on the financingIn all honesty it's disgusting what happened following so many positive news this week.  Put it they way you want this  is even worse a day like yesterday.  But IR can't be changed in 45 days you say... maybe but how come they don't take the time to mention the quality of the centres that are recruiting for th1902.. I mean Sedar Sinai material... not Santa Cabrini or Pierre Boucher hospital for Christ sake... no mention.. it's a deception again but they don't sell their story well and to enough people... go back to Andre De Viller or Rosconi periods.... much more engagement, much more conviction... Paul is a nerd without what it takes to promote is science or company.. sorry
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities